Abuse-Deterrent Opioid Analgesics: A Guide for Clinicians

References

• Compton WM , BoyleM , WargoE. Prescription opioid abuse: problems and responses. Prev. Med.80, 5–9 (2015).
   PubMed Web of Science ®Google Scholar
• Shipton EA , ShiptonEE , ShiptonAJ. A review of the opioid epidemic: what do we do about it?Pain Ther.7(1), 23–36 (2018).
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr , RosenblattM , LeQuangJA. Three years down the road: the aftermath of the CDC guideline for prescribing opioids for chronic pain. Adv. Ther.36(6), 1235–1240 (2019).
   PubMed Web of Science ®Google Scholar
• Alford DP . Opioid prescribing for chronic pain – achieving the right balance through education. N. Engl. J. Med.374(4), 301–303 (2016).
   PubMed Web of Science ®Google Scholar
• Passik SD . Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin. Proc.84(7), 593–601 (2009).
   PubMed Web of Science ®Google Scholar
• Carinci AJ , MaoJ. Pain and opioid addiction: what is the connection?Curr. Pain Headache Rep.14(1), 17–21 (2010).
   PubMed Web of Science ®Google Scholar
• Gasior M , BondM , MalamutR. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgrad. Med.128(1), 85–96 (2016).
   PubMed Web of Science ®Google Scholar
• Vietri J , JoshiAV , BarsdorfAI , MardekianJ. Prescription opioid abuse and tampering in the United States: results of a self-report survey. Pain Med.15(12), 2064–2074 (2014).
   PubMed Web of Science ®Google Scholar
• Nalamachu SR , ShahB. Abuse of immediate-release opioids and current approaches to reduce misuse, abuse, and diversion. Postgrad. Med. doi:10.1080/00325481.2018.15025691–7 (2018) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Miller CJ , DartRC , KatzNP , WebsterLR. Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids. J. Opioid Manag.13(6), 379–389 (2017).
   PubMedGoogle Scholar
• Cicero TJ , EllisMS , KasperZA. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers. Pharmacoepidemiol. Drug Saf.26(1), 56–62 (2017).
   PubMed Web of Science ®Google Scholar
• Butler SF , BlackRA , CassidyTA , DaileyTM , BudmanSH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm. Reduct. J.8, 29 (2011).
   PubMed Web of Science ®Google Scholar
• Green JL , BucherBartelson B , LeLait MCet al. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend.175, 140–145 (2017).
   PubMed Web of Science ®Google Scholar
• Vietri J , MastersET , BarsdorfAI , MardekianJ. Cost of opioid medication abuse with and without tampering in the USA. Clinicoecon. Outcomes Res.10, 433–442 (2018).
   PubMed Web of Science ®Google Scholar
• Passik SD , HeitHA , DeGeorgeM. Reality and responsibility revisited: stakeholder accountability in the effort to develop safer opioids. J. Opioid Manag.13(6), 391–396 (2017).
   PubMedGoogle Scholar
• US Department of Health and Human Services, Food and Drug Administration . Center for Drug Evaluation and Research. Abuse-Deterrent Opioids – Evaluation and Labeling: Guidance for Industry.US Food and Drug Administration, MD, USA (2015). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf
   Google Scholar
• Califf RM , WoodcockJ , OstroffS. A proactive response to prescription opioid abuse. N. Engl. J. Med.374(15), 1480–1485 (2016).
   PubMed Web of Science ®Google Scholar
• Hysingla™ ER (hydrocodone bitartrate) extended-release tablets, for oral use, CII, package insert . Purdue Pharma L.P, CT, USA (2018).
   Google Scholar
• MorphaBond™ ER (morphine sulfate) extended-release tablets, for oral use CII, package insert . Daiichi Sankyo, Inc, NJ, USA (2018).
   Google Scholar
• OxyContin® (oxycodone hydrochloride) extended-release tablets, for oral use, CII, package insert . Purdue Pharma L.P, CT, USA (2018).
   Google Scholar
• Xtampza® ER (oxycodone) extended-release capsules, for oral use, CII, package insert . Patheon Pharmaceuticals, OH, USA (2018).
   Google Scholar
• Embeda® (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, package insert . Pfizer Inc, NY, USA (2018).
   Google Scholar
• Altomare C , KinzlerER , BuchhalterAR , ConeEJ , CostantinoA. Laboratory-based testing to evaluate abuse-deterrent formulations and satisfy the Food and Drug Administration’s recommendation for category 1 testing. J. Opioid Manag.13(6), 441–448 (2017).
   PubMedGoogle Scholar
• Xu X , GuptaA , Al-GhabeishM , CalderonSN , KhanMA. Risk based in vitro performance assessment of extended release abuse deterrent formulations. Int. J. Pharm.500(1–2), 255–267 (2016).
   PubMed Web of Science ®Google Scholar
• Raffa RB , PergolizziJVJr. Opioid formulations designed to resist/deter abuse. Drugs70(13), 1657–1675 (2010).
   PubMed Web of Science ®Google Scholar
• US Department of Health & Human Services, US Food and Drug Administration . Center for Drug Evaluation and Research. Assessment of Abuse Potential of Drugs. Guidance for Industry.US Department of Health & Human Services, MD, USA (2017).
   Google Scholar
• Eaton TA , ComerSD , RevickiDAet al. Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations. Qual. Life Res.21(6), 975–981 (2012).
   PubMed Web of Science ®Google Scholar
• White AG , LeCatesJ , BirnbaumHG , ChengW , RolandCL , MardekianJ. Positive subjective measures in abuse liability studies and real-world nonmedical use: potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs. J. Opioid Manag.11(3), 199–210 (2015).
   PubMedGoogle Scholar
• Cicero TJ , DartRC , InciardiJA , WoodyGE , SchnollS , MunozA. The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS). Pain Med.8(2), 157–170 (2007).
   PubMed Web of Science ®Google Scholar
• Butler SF , BudmanSH , LicariAet al. National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol. Drug Saf.17(12), 1142–1154 (2008).
   PubMed Web of Science ®Google Scholar
• Dart RC , IwanickiJL , DasguptaN , CiceroTJ , SchnollSH. Do abuse deterrent opioid formulations work?J. Opioid Manag.13(6), 365–378 (2017).
   PubMedGoogle Scholar
• Roland CL , SetnikB , BrownDA. Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure. Postgrad. Med129(1), 12–21 (2017).
   PubMed Web of Science ®Google Scholar
• RoxyBondTM (oxycodone hydrochloride) tablets, for oral use, CII, package insert . Daiichi Sankyo, Inc, NJ, USA (2018).
   Google Scholar
• Harris SC , CiprianoA , ColucciSVet al. Intranasal abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med.17(5), 820–831 (2016).
   PubMed Web of Science ®Google Scholar
• Harris SC , CiprianoA , ColucciSVet al. Oral abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med.18(7), 1278–1291 (2017).
   PubMed Web of Science ®Google Scholar
• DiFalco R , KinzlerER , PantaleonC , AignerS. Abuse-resistant, extended-release morphine is resistant to physical manipulation techniques commonly used by opioid abusers. Presented at: PAINWeek 2014.NV, USA, 2–6 September 2014.
   Google Scholar
• Bianchi R , KinzlerE , DiFalcoR , ShahM , AignerS. Extraction testing of a novel extended-release, abuse-deterrent formulation of morphine, morphine ARER, in common household solvents. J. Pain15(Suppl. 4), S77 (2014).
   Web of Science ®Google Scholar
• Kinzler ER , PantaleonC , IversonMS , AignerS. Syringeability of morphine ARER, a novel, abuse-deterrent, extended-release morphine formulation. Am. J. Drug Alcohol Abuse45(4), 377–384 (2019).
   PubMed Web of Science ®Google Scholar
• Webster LR , PantaleonC , ShahMSet al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal drug liking study on a novel abuse-deterrent formulation of morphine–morphine ARER. Pain Med.18(7), 1303–1313 (2017).
   PubMed Web of Science ®Google Scholar
• Webster LR , PantaleonC , IversonM , SmithMD , KinzlerER , AignerS. Intranasal pharmacokinetics of morphine ARER, a novel abuse-deterrent formulation: results from a randomized, double-blind, four-way crossover study in nondependent, opioid-experienced subjects. Pain Res. Manag.2018, 7276021 (2018).
   PubMed Web of Science ®Google Scholar
• Perrino PJ , ColucciSV , ApseloffG , HarrisSC. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin® tablets compared with original OxyContin® tablets in healthy adults. Clin. Drug Investig.33(6), 441–449 (2013).
   PubMed Web of Science ®Google Scholar
• Harris SC , PerrinoPJ , SmithIet al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J. Clin. Pharmacol.54(4), 468–477 (2014).
   PubMed Web of Science ®Google Scholar
• Kopecky EA , FlemingAB , NoonanPKet al. Impact of physical manipulation on in vitro and in vivo release profiles of Oxycodone DETERx®: an extended-release, abuse-deterrent formulation. J. Opioid Manag.10(4), 233–246 (2014).
   PubMedGoogle Scholar
• Gudin J , Levy-CoopermanN , KopeckyEA , FlemingAB. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med.16(11), 2142–2151 (2015).
   PubMed Web of Science ®Google Scholar
• Fleming AB , ScungioTA , GrimaMP , MayockSP. In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres. J. Opioid Manag.12(1), 57–65 (2016).
   PubMedGoogle Scholar
• Brennan MJ , KopeckyEA , MarseillesA , O’ConnorM , FlemingAB. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza® ER compared with OxyContin®. Pain Manag.7(6), 461–472 (2017).
   PubMedGoogle Scholar
• Mayock SP , SaimS , FlemingAB. In vitro drug release after crushing: evaluation of Xtampza® ER and other ER opioid formulations. Clin. Drug Investig.37(12), 1117–1124 (2017).
   PubMed Web of Science ®Google Scholar
• Webster LR , KopeckyEA , SmithMD , FlemingAB. A randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone. Pain Med.17(6), 1112–1130 (2016).
   PubMed Web of Science ®Google Scholar
• Kopecky EA , FlemingAB , Levy-CoopermanN , O’ConnorM , SellersEM. Oral human abuse potential of oxycodone DETERx® (Xtampza® ER). J. Clin. Pharmacol.57(4), 500–512 (2017).
   PubMed Web of Science ®Google Scholar
• Meske D , KopeckyEA , PassikS , ShramMJ. Evaluation of the oral human abuse potential of oxycodone DETERx® formulation (Xtampza® ER). J. Opioid Manag.14(5), 359–372 (2018).
   PubMedGoogle Scholar
• Passik SD , NarayanaA , YangR. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain. Pain Med.15(8), 1365–1372 (2014).
   PubMed Web of Science ®Google Scholar
• Jamison RN , SerraillierJ , MichnaE. Assessment and treatment of abuse risk in opioid prescribing for chronic pain. Pain Res. Treat.2011, 941808 (2011).
   PubMedGoogle Scholar
• Adler JA , Mallick-SearleT. An overview of abuse-deterrent opioids and recommendations for practical patient care. J. Multidiscip. Healthc.11, 323–332 (2018).
   PubMed Web of Science ®Google Scholar
• Rauck RL . Mitigation of IV abuse through the use of abuse-deterrent opioid formulations: an overview of current technologies. Pain Practice19(4), 443–454 (2019).
   PubMed Web of Science ®Google Scholar
• Cohen JP , MendozaM , RolandC. Challenges involved in the development and delivery of abuse-deterrent formulations of opioid analgesics. Clin. Ther.40(2), 334–344 (2018).
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration . FDA analysis of long-term trends in prescription opioid analgesic products: quantity, sales, and price trends (2018). https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM598899.pdf
   Google Scholar
• Dale R , StaceyB. Multimodal treatment of chronic pain. Med. Clin. North Am.100(1), 55–64 (2016).
   PubMed Web of Science ®Google Scholar
• Tompkins DA , HobelmannJG , ComptonP. Providing chronic pain management in the “fifth vital sign” era: historical and treatment perspectives on a modern-day medical dilemma. Drug Alcohol Depend.173(Suppl. 1), S11–S21 (2017).
   PubMedGoogle Scholar